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Abstract: Central pain is an enigmatic, intractable condition, related to destruction of thalamic areas, resulting in likely loss of   inhibitory 
synaptic transmission mediated by GABA. It is proposed that treatment of central pain, a localized process, may be treated by GABA 
supplementation, like Parkinson’s disease and depression. At physiologic pH, GABA exists as a zwitterion that is poorly permeable 
to the blood brain barrier (BBB). Because the pH of the cerebral spinal fluid (CSF) is acidic relative to the plasma, ion trapping may 
allow a GABA ester prodrug to accumulate and be hydrolyzed within the CSF. Previous investigations with ester local anesthetics may 
be applicable to some GABA esters since they are weak bases, hydrolyzed by esterases and cross the BBB. Potential non-toxic GABA 
esters are discussed. Many GABA esters were investigated in the 1980s and it is hoped that this paper may spark renewed interest in 
their development.
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Definitions
Central pain is defined as pain caused by a lesion of 
the central nervous system (CNS). With broadening 
of the term “lesion”, other clinical pain conditions 
such as deafferentation, phantom, and delusional pain 
conditions can be considered central pain, but for the 
purposes of this paper, central pain will refer to the 
enigmatic intractable pain condition primarily caused 
by destruction of areas of the thalamus or projections 
from  the  thalamus  to  the  cortex  (thalamo-  cortical 
tracts)  and  other  closely  related  areas  of    neural 
destruction including supportive glial cells, shell wide 
dynamic range neurons of the thalamus and the zona 
incerta often injured after stroke.1 Central pain from 
trauma to the spinal cord or spinal-thalamic tract is 
not considered at this time.
Is central pain caused  
by Depletion of GABA?
For over 100 years, the etiology of central pain has 
puzzled scientists and clinicians because there is 
not a uniform and consistent anatomic lesion that 
can  explain  the  symptoms  even  though  thalamic 
or   thalamic cortical tracts are frequently injured. 
Since the anatomy is variable and the biochem-
istry  is  obscure,  the  pharmacological  therapy  as 
discussed in this paper is based on the following 
information:
1) Clinical reports of central pain relief after the 
administration  of  intrathecal  baclofen,  a  GABA-B 
agonist.2–6 2) Clinical trials in which tricyclic anti-
depressant  therapy  produce  analgesia  presumably 
through reversal of GABA inhibition.7 3) Laboratory 
reports in animals in which application of GABA in 
the cerebral cortex produced analgesia and intrath-
ecal  GABA  antagonists  produced  allodynia  and 
hyperalgesia.8
Based on clinical observations, one hypothesis also 
supports the role of GABA deficiency in the etiology 
of central pain and is as follows: In the three neuron 
network of nocioceptive transmission, a destructive 
procedure, including cordotomy, rhizotomy, neurec-
tomy, and neurolysis of first order neurons produces 
an initial analgesic response because it is likely that 
the  net  neuronal  excitation  and  glutamate:GABA 
ratio has been reduced. Also, the analgesia produced 
by cervical cordotomy, ablation of the spinal thalamic 
tracts,  reliably  produces  analgesia.9    However, 
over  time,  with  regeneration  and  recruitment,  the 
  analgesia  from  these  destructive  lesions  may  be 
  transformed into pain. Since destruction of the first or 
second order excitatory neurons produces analgesia, 
then it seems plausible that destruction of the third 
order neurons produces central pain because these 
neurons are net inhibitory and there is a deficiency 
of  GABA  or  increase  in  the  glutamate:  GABA 
ratio.    Neural  destruction  may  cause  central  pain 
by  depleting  GABA  via  a  number  of  mechanisms 
including  inhibition  of  glutamate  decarboxylase 
(GAD),  restricting  glutamate  substrate,  paralyzing 
reuptake  and  increasing  the    percentage  of  GABA 
uptake by glial cells. However the paracrine and auto-
crine effects of GABA potentially confuse the link 
between central pain and GABA especially when one 
tries to define GABA effects as exclusively related to 
  synaptic transmission.10,11
This paper is not the first publication to link cen-
tral pain and GABA deficiency and addresses a basic 
hypothesis  without  taking  into  account  possible 
other neurotransmitters and collateral pathways.12,13 
My  hope  is  to  present  a  potential  therapy  for  the 
treatment of central pain, an intractable devastating 
condition, with selected GABA esters including spe-
cial consideration to parallel pharmacologic proper-
ties with local ester anesthetics that may speed drug 
development.
Baclofen and central pain
The  most  commonly  prescribed  GABA  agonist, 
baclofen,  binds  to  the  metabotropic  heterodimeric 
GABA-B receptor and is not antagonized by bicucul-
line, a GABA-A agonist.14 Because oral dosing poorly 
permeates the blood brain barrier (BBB), intrathecal 
baclofen  therapy  is  indicated  for  the  treatment  of 
spasticity from pyramidal tract disease or multiple 
sclerosis  and  has  been  reported  to  relieve  central 
pain.2–5 Intrathecal administration of any medication 
has  many  potential  problems,  including  infection, 
bleeding, catheter migration, obstruction of tubing, 
replacement  of  generators,  granuloma  formation, 
refilling mishaps and expense.15 This author believes 
that spinal infusion of a GABAergic medication is not 
a sustainable long-term therapy for the large number 
of patients who suffer from central pain.GABA esters provide analgesia for central pain
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can GABA Replacement Treat  
Central Pain Instead of Specific 
synthetic Agonists?
In present medical therapy, localized deficiencies of 
a neurotransmitter or naturally occurring substrate 
are treated by direct or indirect replacement even 
though the replacement therapy has significant side 
effects.  1)  In  Parkinson’s  disease,  the  local  defi-
ciency in dopamine within the substantia nigra is 
treated with L-dopa which is converted to dopamine, 
a ubiquitous neurotransmitter. Systemic effects like 
hypotension and constipation are tolerated for the 
treatment of the CNS dopamine deficiency. 2) Mono-
amine  and  serotonin  therapy  for  the  treatment  of 
depression may produce unwanted systemic effects 
like hypotension, tachycardia, and dry mouth, but 
the  benefits  of  therapy  outweigh  the  undesirable 
systemic side effects. 3) Numerous examples exist 
in the field of endo  crinology (panpituitary, adrenal, 
and thyroid deficiencies) where estimating hormone 
replacement  is  lifesaving  and  the  side  effects  are 
tolerated.
Because the molecular structure is not restrained, 
GABA freely rotates around all three carbon atoms 
and  there  exists  a  myriad  of  conformations  that 
makes  synthesis  of  active  agonists  challenging. 
There are many subtypes of GABA receptors, evolv-
ing through permutations of the subunits that may 
explain  why  GABA  deficiency  is  associated  with 
many disease states.16 Matching a specific GABA 
receptor  subtype  agonist  to  the  variable  lesions 
of central pain and introducing a subtype specific 
GABA agonist into the delicate CNS would be a 
significant  undertaking.  For  example,  vigabatrin, 
a GABA agonist with good bioavailability and anal-
gesic action, produced visual field defects in 1/3 of 
patients  during  therapy  and  tiagabine,  a  selective 
inhibitor of GABA transport (GAT1), took twenty 
years to bring to market.17,18
Although  designing  and  developing  a  central 
pain-specific  GABA  prodrug,  with  known  effects 
inside and outside the CNS would be ideal, it would 
not be easy. From what we know about the possible 
toxicity of GABA, it would seem unlikely that central 
nervous system replacement to physiologic levels of 
2 nmoles/ml would be detrimental. The following 
supports this proposition: 1) Systemically injected 
doses  of  GABA  of  up  to  1  g/kg  (9.7  mmol/kg) 
have little effect on motor activity in rats   possibly 
because there is rapid metabolism by GABA-  alpha-
oxoglutarate    aminotransferase  (GABA-T)  that 
  prevents accumulation and excessive serum levels.19 
2) There are no reports of major side effects from 
large  doses  of  GABA  supplements  ingested  by 
athletes. 3) In humans, the LD50 for GABA has not 
been determined. 4) Because of hydrolysis, effects 
of  elevated  serum  levels  of  prodrug  would  likely 
be  muted,  as  known  to  occur  when  comparing 
CNS  toxicities  of  ester  local  anesthetics  to  direct 
cardiac toxicities of amide local anesthetics. Thus, 
direct  replacement  therapy  with  GABA,  may  be 
more  achievable  even  with  known  GABA  effects 
outside the CNS such as activity on the peripheral 
nervous  system,  pancreas,  smooth  muscle,  female 
reproductive organs and   cerebral blood vessels.
After Degradation by plasma 
esterases, Would enough GABA  
ester exist to cross the BBB?
This is an unknown in humans, but the patented work 
of Victor  E.  Shashoua,  “GABA  esters  and  GABA 
analog esters” along with the well-developed pharma-
cology of ester type local anesthetics would suggest 
that some ester will be available to act on the CNS.19 
Procaine and 2-chloroprocaine, two ester local anes-
thetics  administered  intravenously,  intramuscularly, 
or  subcutaneously,  will  be  hydrolyzed  by  plasma 
butyrylcholinesterase  (pseudocholinesterase),  but 
sufficient  ester  will  penetrate  the  BBB  to  induce 
significant CNS effects and in some cases temporary 
relief of pain.20 Therefore, even with plasma esterase 
concentrations 20–100 fold greater than CSF levels, it 
is still possible to safely introduce an ester   compound 
into the central nervous system.21
can GABA esters penetrate the BBB?
To date, discovering GABA analogs that penetrate the 
BBB by designing GABA conjugates to known trans-
porter systems, increasing lipophilic GABA analogs, 
neutralizing one or both charges on GABA by cyclici-
zation, or developing molecular “Trojan horses” has 
had limited success.22,23 Physical methods to disrupt the 
integrity of the BBB, focusing intracranial ultrasound 
waves or infusing osmotically active substances such Goldberg
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as mannitol into the carotid artery have opened the 
endothelial tight junctions of the BBB, but have not 
become    acceptable    clinical  therapies.23,24  Although 
many calculations and measurements of the in vitro 
octanol/water partition coefficient, (logP), reflecting 
BBB permeability, can be determined, a better mea-
surement of BBB penetration is the Brain Penetra-
tion Index (BPI) which is the amount of compound 
present per gram of brain tissue as a percent of the 
amount per gram of liver tissue. In an animal model, 
the BPI (with GABA standardized as 1) of the follow-
ing GABA esters showed that selected GABA esters 
can cross the BBB:19
BPI Kow
GABA 1 0.004
3-Gluosyl-GABA 104 0.21
Dexamethasone-GABA 81 0.9
Butyl-GABA 74
Cholesteryl-GABA 25 110
Inosital-GABA 11
can the Difference Be  tween  
csF and plasma pH enhance  
Ion Trapping of GABA esters?
Dr. Povl Krogsgaard-Larsen has discussed the poten-
tial development of amino acid analogs of GABA that 
would penetrate the BBB in the   non-ionized form 
and increase drug CSF levels through ion   trapping.25 
The decrease in buffer proteins,   particularly hemo-
globin,  the  increase  in  PCO2  from  inequality  of 
  diffusion, and increased lactic acid production from 
glycolysis,  produce  a  Gibbs    Donnan  equilibrium 
and pH gradient where the pH of CSF is approxi-
mately 0.09–0.10 pH units more acidic than the pH 
of the plasma.26 As a consequence of this pH gradi-
ent, ion trapping of selected GABA esters within the 
CSF likely occurs and is similar to the pH depen-
dent ion trapping of local anesthetics across the pla-
centa of a distressed acidotic fetus (a phenomena 
well recognized by obstetrical anesthesiologists).27 
Also, ion trapping was an important consideration 
for the development of the proton pump inhibitors, 
since the highly acidic environment of the gastric 
parietal  cells  permitted  intracellular  trapping  of 
medications like omeprazole.28 Because this trap-
ping effect within the CSF is not well appreciated 
in the   literature and is important for understanding 
the pharmacokinetics of GABA esters, an example 
  follows: If the pKa value of a hypothetical GABA 
ester is 10, the pH of the CSF is 7.3 and the pH 
of plasma 7.4 then this effect may be approximated 
for  comparison  between  the    concentrations  of 
  protonated plasma ester [HB+
plasma] and protonated 
CSF ester [HB+
csf] as:
[HB+
plasma] = [H+
plasma] + [Bplasma] ∼ {BBB}∼ [Bcsf] + [H+
csf] = [HB+
csf]
pKa - pHplasma = log([HB+
plasma]/[Bplasma])  pKa - pHcsf = log ([HB+
csf]/[Bcsf])
2.6 = log ([HB+
plasma]/[Bplasma])  2.7 = log([HB+
csf]/[Bcsf])
Antilog of equations
398 = [HB+
plasma]/[Bplasma]  501 = [HB+
csf]/[Bcsf]
[Bplasma] ∼ [Bcsf]
[HB+
plasma]/398 = [Bplasma]  [Bcsf] = [HB+
csf]/501
[HB+
plasma]/398 = [HB+
csf]/501
[HB+
csf]/[HB+
plasma] = 501/398 = 1.26GABA esters provide analgesia for central pain
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Therefore  the  CSF  concentration  of  protonated 
GABA ester is approximately 1.26 × the plasma con-
centration from ion trapping effects secondary to pH 
differences between plasma and CSF.
Why are esters of GABA  
Ideal prodrugs?
1. Easy to synthesize
Protecting the amine group with t-butoxycarbonyl 
derivatives  (t-BOC),  numerous  GABA  esters 
have  been  synthesized  through  condensation  of 
the desired alcohol in acid milieu with GABA.19 
Synthesis  of  more  complex  GABA  esters,  such 
as glyceryl and inositol derivatives, has required 
protection of various OH groups that are not to 
be  esterified.19  Overall,  with  reliable  protection 
groups many GABA esters can be synthesized.
2. Inductive effects of ester groups
Although difficult to estimate, the electron inductive 
effects of the ester group preferentially favors the 
free base form and penetration through the BBB.
3. Ester vs. amide prodrug
Although other conjugates of GABA such as amides 
may be more stable in vivo, it is unlikely that they 
would be hydrolyzed by an amidase within the CNS. 
Lidocaine and bupivacaine are amide local anes-
thetics commonly administered intrathecally and 
their action is terminated by redistribution rather 
than enzymatic degradation within the CSF.29 Also, 
GABA amides of nortriptyline and fluoxetine were 
found to be active, but GABA was not found to be 
a metabolite in the plasma.30   Picamilon, the niacin 
amide of GABA, available as a dietary supplement 
in  the  United  States  and  widely  investigated  in 
Russia, has not been shown to be hydrolyzed by an 
amidase in the CSF.31 A further advantage of ester 
conjugates of GABA vs. amide conjugates is that, 
in general, amide conjugates of GABA are more 
difficult to synthesize.
4. Esterases exist in the CSF and plasma32
Esterases,  acetylcholinesterase,  butyrylcholinest-
erase and perhaps others which could hydrolyze the 
GABA ester exist in the plasma, blood, liver, kid-
ney, and cerebral spinal fluid. The concentration of 
CSF butyrylcholinesterase is approximately 1/20–
1/100 of the plasma concentration.33 Much work 
has been done on the genetics of cholinesterase and 
butyrylcholinesterase  because  the  neuromuscular 
blocking drug succinylcholine, commonly used in 
anesthesiology,  undergoes  ester  hydrolysis.  Pro-
longing the actions of local ester anesthetics and 
succinylcholine, a small percentage of the popu-
lace has an autosomal recessive trait in which they 
express an atypical butyrylcholinesterase. Others 
may  have  metabolic  conditions  associated  with 
liver disease, uremia, malnutrition, pregnancy and 
medications that result in decreased amounts of this 
enzyme. Many laboratories provide assays of cho-
linesterases, both acetylcholinesterse and butyryl-
cholinesterse levels, that may need to be measured 
prior to treatment with a GABA ester.34
5. Comparison to the ester local anesthetic model
Since ester local anesthetics have been in use for over 
100 years there is a wealth of clinical data regard-
ing the bioavailability, redistribution, metabolism, 
and excretion of ester local anesthetics that could 
be very useful for the development of a GABA ester 
medication. Selected GABA esters and ester local 
anesthetics are weak bases with a lipophilic termi-
nus and may have similar pKa values and similar 
pharmacokinetic  profiles.  Methodologies  used  to 
establish efficacy and safety for ester local anesthet-
ics may translate to GABA ester development.
6. Safety
Compared with other GABA conjugates and ago-
nists,  introducing  a  GABA  ester  into  the  CNS, 
metabolized by esterases, may be the least danger-
ous therapy aimed to replenish GABA deficiency 
in patients suffering from central pain. This author 
feels it is essential that the prodrug be metabolized 
to GABA and a known non-toxic metabolite. This 
excludes many of the GABA esters described in 
the literature. Even with these considerations, the 
potential toxicity of the prodrug, itself, including 
the plasma levels of prodrug required to compete 
with degradation from plasma esterases could pre-
clude development of a safe drug.
Literature Review of Animal 
pharmacology of selected  
GABA esters
1. GABA  esters  of  perphenazine  and  fluphenazine 
were synthesized and investigated by Nudelman Goldberg
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et al. The perphenazine conjugate was found to be 
rapidly orally absorbed, cross the BBB and produce 
neuroleptic activity with reduced   extrapyramidal 
symptoms  and  sedation. Autoradiography  of  rat 
brain slices did not differentiate whether GABA 
had been hydrolyzed from the compound.35
2. Jacob et al synthesized two lipid esters of GABA 
and showed that these compounds could penetrate 
the BBB 75 and 127 fold greater than that of free 
GABA after systemic administration, and the com-
pounds were hydrolyzed into GABA and lipid by 
brain  homogenates.  Dose  response  changes  in 
activity were described, but no toxicity data were 
reported.35
3. Carelli  et  al  synthesized  a  GABA  benzyl  ester 
linked to a tetrahydrodinicotinamide salt that was 
systemically injected and produced GABA mimetic 
effects, but no toxicity data were reported.37
4. Shashoua synthesized the n-butyl, linolenoyl, cho-
lesteryl and dexamethasone esters of GABA that 
crossed the BBB as evidenced by BPI data (see 
earlier table). Only the cholestryl ester was active 
in reducing the general activity test in mice. He 
subsequently synthesized glyceryl esters of GABA 
and showed that they penetrated the BBB. This led 
to his conclusion that “in fact there seems to be no 
blood-barrier for the lipid derivatives”. Systemic 
administration of these compounds produced mod-
est effects on general locomotor and bicuculline-
induced seizure activity in mice. Also synthesized 
were a wide variety of GABA glucose-3-esters and 
gamma-vinyl esters.19
Discussion of potential  
preferred GABA esters
Unless a suitable enteric coating were developed, it is 
unlikely that any of the proposed GABA esters would 
be absorbed by the oral route because of inactivation 
in the stomach. However, it is likely that some of these 
medications could be absorbed through the mucosa, 
skin, or muscle similar to esters of local anesthetics 
and testosterone. The hydrolysis of the prodrug should 
yield GABA and non-toxic metabolites within the CSF 
preferably of substances already familiar to the central 
nervous system. A few examples of GABA esters and 
cleavage products that may meet these criteria will be 
discussed. These esters are illustrated in neutral form 
but are most likely to be stored and administered as 
hydrochloride salts to avoid transamidation: 1) ethyl 
ester GABA 2)   glucose ester GABA 3) diethylamino 
ethanol  (DEAE),  a  metabolite  of  intrathecal  local 
anesthetics procaine and tetracaine, ester conjugated 
to  GABA  4)  dehydroascorbic  acid  ester  GABA 
5) cholesterol ester GABA 6) inositol ester GABA.
1. Ethyl ester GABA (ethyl 4 aminobutyrate) (Fig. 1) 
is commercially available, soluble in water, may 
cross the BBB since it is probably more perme-
able into the CNS than the double charged GABA 
zwitterion  and,  in  addition,  related  n-butanol 
ester GABA has been shown to cross the BBB. 
Preliminary  work  has  shown  that  esterase  in 
plasma and CSF hydrolyze ethyl 4 aminobutyrate 
into GABA and ethyl alcohol.38 Calculation of the 
ethanol concentration to replace estimated physi-
ologic levels of GABA is far below physiologic 
effects or detection levels (0.01%) in most ethanol 
assays and is calculated as: 
Calculation of 0.01%  ethanol level in mmoles per ml 
mw ethanol 46 mg/mmole 
0.01% ethanol = 0.01 mg/100 mg ∼0.1 mg/ml × 1 
mmole/46 mg 
2.1 × 10-3 moles of ethanol/ml csf vs. 2.0 × 10-9 moles 
GABA/ml csf (physiologic replacement).
Therefore,  intrathecal  hydrolysis  of  ethyl  ester 
GABA  probably  produces  an  acceptable  quantity 
of  ethanol,  oxidized  by  catalase  to  acetaldehyde, 
and probably not detectable by motor or behavioral 
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Figure 1. ethyl ester GABA.
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Figure 2. Glucose ester GABA.GABA esters provide analgesia for central pain
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deficits. However, systemic effects of ethanol from 
plasma  hydrolysis  of  ethyl  ester  GABA  could  be 
significant.
2. Glucose ester GABA (Fig. 2) has a BPI of 104 in 
mice and Kow = 0.21 so it likely crosses the BBB 
in humans.19 Transport into the CSF may be from 
active glucose transport via GLUT-1, passive dif-
fusion, or both. This compound may be hydro-
lyzed to glucose and GABA. One would expect 
with supplementation of GABA to 2 nmole/ml, 
the  small  addition  of  glucose  to  the  CSF  and 
plasma as a consequence of the ester hydrolysis 
of  glucose  ester  GABA  would  likely  produce 
insignificant  physiologic  effects.  Average  CSF 
glucose  concentration  of  60  mg/dl    converts  to 
3,000 nmoles/ml
3. Diethylamino ethyl ester GABA (Fig. 3), a deriva-
tive of the local ester anesthetics, 2-chloroprocaine 
and tetracaine, may be a possible choice for replen-
ishing GABA within the CNS. Procaine and tet-
racaine, commonly administered ester intrathecal 
anesthetics, have been in clinical use for decades 
with rare reports of neurotoxicity. Although, the 
majority (97%) of intrathecal procaine and tetra-
caine exits the CSF through redistribution, some 
must be degraded to diethylamino ethanol (DEAE) 
and benzoic acid because esterases are present in 
the CSF.39 Assuming 3% of the commonly adminis-
tered 10 mg intrathecal dose of tetracaine is hydro-
lyzed, this would yield an intrathecal concentration 
of DEAE much higher than would be anticipated 
from the hydrolysis of DEAE ester GABA: 
Ten (10 mg) tetracaine HCl × 1 mmole/301 mg × 
0.03/150 ml csf = 6.6 × 10-6 mmoles/ml = 6.6 × 10-9 
moles/ml compared to 2 × 10-9 moles of GABA/ml.
For  100  mg  procaine  ×  1  mmole/272  mg  ×  0.03/ 
150 ml csf = 7.35 × 10-5 mmoles/ml  = 7.35 × 10-8 
moles/ml compared to 2 × 10-9 moles of GABA/ml.
4. Dehydroascorbic acid, the oxidized form of vita-
min C, is actively carried into the CNS by GLUT-1 
transporter, producing vitamin C levels in the brain 
that are 10 fold greater than other tissues. It is not 
known whether the transporter would recognize 
dehydroascorbic  acid  ester  GABA,  (Fig.  4)  but 
additional vitamin C introduced in the CNS by 
hydrolysis  of  this  GABA  would  probably  have 
low toxicity.
5. Cholesteryl-GABA (Fig. 5) easily crosses the BBB 
in mice (Kow = 110), and probably in humans, in 
amounts  needed  for  GABA  replacement,  and  it 
may not be toxic.19 Free and esterified cholesterol 
concentrations range between 3.1–5.4 microgm/ml 
in the CSF or approximately 2.5 mmole/ml, more 
than 1000 times greater than the 2 nmole/ml con-
centration of GABA, and therefore would prob-
ably be acceptable additional cholesterol.40
6. Inositol ester GABA (Fig. 6) with a BPI of 11 may 
have fair penetration of the BBB but is included 
in this list of GABA esters because inositol is 
naturally found in significant quantities within 
the CSF.
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Figure 4. Dehydroascorbic acid ester GABA.
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Figure 5. Cholesteryl GABA.Goldberg
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GABA esters and patent protections
After filing on May 7, 1990, on September 24, 1991, the 
United States Patent Office issued a   patent   protecting 
numerous  GABA  esters  to  McClean    Hospital, 
a   Harvard University affiliate.19 For many classes of 
claimed GABA esters this patent describes   synthesis 
and biological activity including   radiolabeled brain 
uptake, locomotor and anticonvulsant activity. It is 
unlikely that this patent had any significant impact 
on the further development of GABA esters espe-
cially  since  the  recent  license  was  not  renewed.41 
Dr.   Victor E. Shashoua, (1929–2008) is to be given 
credit for much of the initial development of these 
potential prodrugs and this author does not know why 
they were not further tested. If a successful GABA 
ester were brought to market exclusive rights could 
be available from the FDA.
conclusion
Based  on  neurophysiology  and  neuropharmacol-
ogy, devastating central pain caused by lesions of 
the inhibitory neurons of the thalamus and thalamo-
  cortical tracts probably produces GABA deficiency. 
If post synaptic receptors are functional after brain 
injury, replenishing GABA may provide relief of 
symptoms. At physiologic pH, GABA exists as a 
zwitterion  impermeable  to  the  blood  brain  bar-
rier,  but  selected  GABA  esters  of  ethanol,  glu-
cose,  diethamino  ethanol,  dehydroascorbic  acid, 
cholesterol, and inositol may cross the BBB and 
replace  GABA  in  the  CNS  provided  that  central 
nervous system esterases can hydrolyze the prod-
rug. GABA esters possess chemical similarities to 
local ester anesthetics for which there is extensive 
laboratory and clinical experience, some of which 
may aid in the development of these prodrugs. Ion 
trapping and ester electron inductive effects may 
favor increasing CSF levels of the prodrug. This 
author  feels  that  GABA  esters  with  the  greatest 
safety within the CNS should be hydrolyzed by an 
esterase into GABA as well as a compound with a 
known   exposure and toxicity to the human CNS. 
Even with these   considerations, the prodrug or the 
plasma level of prodrug required to offset degrada-
tion by hydrolysis could limit the effectiveness of 
this strategy. This paper hopes to spark interest in 
development of GABA ester analogs as novel anal-
gesics for central pain and perhaps other conditions 
of  the  CNS  where  GABA  deficiency  is  thought 
to exist.
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